';

Categories

  • Evolution Infographics
  • News & Analysis
+44 141 248 2026info@evolution-bio.comNewsletter Sign-UpDownload Our BrochureEvolution Executive Search
logo
Evolution Bioscience
logo
  • Home
  • Clients & Core Services
  • News & Analysis
    • The Future of BioManufacturing
  • IPO Tracker

Monthly Archives: October 2018

Evolution Infographics
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
More
Share
Evolution Infographics
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
More
Share

RECENT POSTS

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

DATA VISUALISATIONS

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

About Us

Evolution Bioscience is a global consultancy firm, specialising in market intelligence, strategy formulation, technology transfer and commercialisation services, covering the full range of Biotechnology sectors.

Recent Posts

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
2016 © Evolution Bioscience / Darwin Hutton Partners
Evolution Bioscience